Keywords: Elan, Biogen Idec, Tysabri, FDA warnings, PML, Risk factors

Elan shares decline 5.8% on new US FDA call for stronger warning on Tysabri

Article | 8 February 2010

Irish drugmaker Elan saw its share price drop 5.8% to 5.05 euros, after it was revealed that the US Food and Drug Administration had found that the risk of a potentially fatal brain disorder with the firm’s multiple sclerosis drug Tysabri (natalizumab) increases as patients receive more infusions and called for stronger warnings. The agency did, however, reiterate its views that the benefits for MS patients associated with the drug still outweigh the risks.

The prescribing information for Tysabri, co-marketed with US biotechnology company Biogen Idec - originator of the drug - will be updated to warn about the higher risk of use of the drug over time. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in